Loading…
Mirum Pharmaceuticals, Inc. is projected to rise to $162.62 by 2027, a +33% move from its current price of $122.13. MIRM is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $118.99 | $122.21 | $125.52 | +0.07% |
| Jul 14 | $117.76 | $122.29 | $127.00 | +0.13% |
| Jul 15 | $116.84 | $122.38 | $128.17 | +0.20% |
| Jul 16 | $116.09 | $122.46 | $129.18 | +0.27% |
| Jul 17 | $115.44 | $122.54 | $130.08 | +0.33% |
| Jul 18 | $114.86 | $122.62 | $130.91 | +0.40% |
| Jul 19 | $114.33 | $122.70 | $131.69 | +0.47% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $114.33 | $122.70 | $131.69 | +0.47% |
| Week 2 | $111.56 | $123.28 | $136.23 | +0.94% |
| Week 3 | $109.59 | $123.86 | $139.98 | +1.41% |
| Week 4 | $108.04 | $124.44 | $143.33 | +1.89% |
| Week 5 | $106.75 | $125.02 | $146.42 | +2.37% |
| Week 6 | $105.65 | $125.61 | $149.34 | +2.85% |
| Week 7 | $104.68 | $126.20 | $152.14 | +3.33% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.
The company is also involved in the commercialization of Cholbam, a cholic acid capsule, and Chenodal, a tablet, and its pipeline includes Volixibat (Phase 2b) for cholestatic liver diseases; Brelovitug (Phase 2) for chronic HDV infection; and MRM-3379 (Phase 2) for fragile X syndrome. Mirum has collaboration and license agreements with several large partners and asset purchases with others, reflecting a broad network of collaborations.
The company was incorporated in 2018 and is headquartered in Foster City, California. It maintains collaboration agreements with Shire International GmbH; license agreements with Pfizer Inc.; Sanofi-Aventis Deutschland GmbH; Novartis Pharma AG; Lonza Ltd.; Enthorin Therapeutics, LLC and Dart Neuroscience LLC; asset purchase agreements with Asklepion Pharmaceuticals, LLC and Travere Therapeutics, Inc.; and a license and manufacturing agreement with LGM Pharma."
Mirum Pharmaceuticals (MIRM) trades at $123.77 with a market capitalization of $7.15B and is ranked 5495. The current price sits within a longer-term forecast that envisions meaningful upside, particularly from 2027 onward. The multi-year outlook shows a path of growing average prices and expanding ROIs, highlighted by a 2030 average near $335.80 and a 2050 average near $2,416.69.
The forecasted trajectory paints bullish sentiment across most years beyond 2026, with substantial upside potential in later decades. For example, the 2030 forecast highlights an average price of $335.80 (min $254.67, max $475.18) and a ROI of 171.3%, while the 2050 forecast shows an average of $2,416.69 (min $1,474.03, max $4,239.89) and a ROI of 1852.6%.
Overall, the outlook suggests a long-run uptrend from a current level around $123.77, supported by bullish sentiment in the majority of forecast years after 2026, including 2031 through 2050."
A major floor 36.6% below — a decisive break under it would weaken the trend.
The nearest floor, 24.8% below — buyers have tended to step in here.
The nearest ceiling, 5.3% above — a clean break opens room to run.
A major ceiling 23.6% above — clearing it would confirm fresh momentum.
Key MIRM support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of MIRM market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $125.72 | Sell | $124.77 | Sell |
| MA 10 | $123.85 | Sell | $122.39 | Sell |
| MA 20 | $115.01 | Buy | $116.75 | Buy |
| MA 50 | $105.80 | Buy | $108.05 | Buy |
| MA 100 | $100.07 | Buy | $101.07 | Buy |
| MA 200 | $89.36 | Buy | $90.55 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 60.44 | Neutral |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | 52.34 | Neutral |
| Williams %R (14) | -30.96 | Info |
| MACD (12,26,9) | 0.71 | Buy |
| ROC (12) | 9.96 | Buy |
| Bollinger %B (20,2) | 0.67 | Neutral |
| Stochastic %K (14) | 69.04 | Neutral |
| TRIX (15) | 0.87 | Buy |
| Awesome (5,34) | 18.48 | Buy |
| Ultimate (7,14,28) | 62.03 | Neutral |
| Momentum (10) | 4.85 | Buy |
| Aroon Osc (25) | 92.00 | Buy |
| Hull MA (9) | 128.05 | Sell |
| ADX (14) | 30.26 | Buy |
| ATR (14) | 3.05 | Info |
The 30-day picture places the stock within a tight, constructive band: the 30-day range runs from $105.97 to $144.56. This reflects a constructive near-term posture with recent upside potential intact.
Technically, the setup shows bullish sentiment with RSI14 at 70. The stock trades above the SMA50 of $99.90 and the SMA200 of $86.91, with established near-term support at $91.83 and resistance at $117.28. These levels frame a cautious but positive short-term view within the current trading window."
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $75.56 | $122.13 | $169.17 | 0% | Neutral | |
| $129.73 | $162.62 | $215.50 | +33% | Bullish | |
| $156.75 | $201.91 | $277.44 | +65% | Bullish | |
| $207.93 | $273.94 | $387.27 | +124% | Bullish | |
| $255.77 | $343.74 | $497.69 | +181% | Bullish | |
| $264.53 | $362.02 | $535.20 | +196% | Bullish | |
| $293.46 | $408.44 | $615.24 | +234% | Bullish | |
| $339.43 | $479.95 | $735.32 | +293% | Bullish | |
| $369.27 | $530.05 | $824.85 | +334% | Bullish | |
| $471.46 | $686.52 | $1,083.93 | +462% | Bullish | |
| $666.49 | $1,035.79 | $1,737.84 | +748% | Bullish | |
| $1,402.60 | $2,437.47 | $4,468.62 | +19.0x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $75.56 | $122.13 | $144.30 | +0.00% |
| August 2026 | $105.48 | $124.41 | $150.63 | +1.87% |
| September 2026 | $109.30 | $129.81 | $158.89 | +4.34% |
| October 2026 | $108.96 | $130.17 | $160.79 | +0.27% |
| November 2026 | $108.38 | $130.12 | $161.97 | -0.04% |
| December 2026 | $111.88 | $134.95 | $169.17 | +3.71% |
Click any year to see its month-by-month MIRM forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, MIRM could reach as high as $169.17, with a base case around $122.13 and support toward $75.56 — roughly 0% from $122.13. Price action looks broadly range-bound.
Expect MIRM to range from $129.73 to $215.50 through 2027. The $162.62 average target implies a +33% move from current prices. That is up +33% on the projected 2026 average. Buyers look set to stay in control over this stretch.
The MIRM price prediction for 2028 points to an average of $201.91 (low $156.75, high $277.44) — a potential gain of +65% on today's $122.13. Momentum favours further upside here.
In 2029, MIRM is projected to trade between $207.93 and $387.27, averaging $273.94 — a potential gain of +124% from today's $122.13. That is up +36% on the projected 2028 average. Buyers look set to stay in control over this stretch.
Mirum Pharmaceuticals, Inc.'s 2030 outlook centres on $343.74, within a $255.77 to $497.69 range. That is up +25% on the projected 2029 average. That marks a +181% change versus current levels. Momentum favours further upside here.
By 2031, MIRM could reach as high as $535.20, with a base case around $362.02 and support toward $264.53 — roughly +196% from $122.13. Buyers look set to stay in control over this stretch.
Expect MIRM to range from $293.46 to $615.24 through 2032. The $408.44 average target implies a +234% move from current prices. That is up +13% on the projected 2031 average. Momentum favours further upside here.
The MIRM price prediction for 2033 points to an average of $479.95 (low $339.43, high $735.32) — a potential gain of +293% on today's $122.13. Buyers look set to stay in control over this stretch.
In 2034, MIRM is projected to trade between $369.27 and $824.85, averaging $530.05 — a potential gain of +334% from today's $122.13. That is up +10% on the projected 2033 average. Momentum favours further upside here.
Mirum Pharmaceuticals, Inc.'s 2035 outlook centres on $686.52, within a $471.46 to $1,083.93 range. That is up +30% on the projected 2034 average. That marks a +462% change versus current levels. Buyers look set to stay in control over this stretch.
By 2040, MIRM could reach as high as $1,737.84, with a base case around $1,035.79 and support toward $666.49 — roughly +748% from $122.13. Momentum favours further upside here.
Expect MIRM to range from $1,402.60 to $4,468.62 through 2050. The $2,437.47 average target implies a +19.0x move from current prices. That is up +135% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in MIRM today (≈ 8.187996 MIRM) could be worth
$19,958.02
+$18,958.02 (+1896%) by 2050 · US Dollar
Based on the average projected MIRM price of $2,437.47 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in MIRMwould be worth at today's price.
$1,000 invested in MIRM on Jul 10, 2025 (≈ 18.864366 MIRM) would be worth
$2,303.9
+$1,303.9 (+130.4%) today · 2.30× · US Dollar
Based on a MIRM entry price of $53.01 vs. today's $122.13.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $125.59 | $972.45 | -2.8% |
| 1 month ago | $94 | $1,299.26 | +29.9% |
| 3 months ago | $95.2 | $1,282.88 | +28.3% |
| 6 months ago | $89.5 | $1,364.58 | +36.5% |
| 1 year ago | $53.01 | $2,303.9 | +130.4% |
| All time (5.0y) ago | $16.02 | $7,623.6 | +662.4% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our MIRM forecast.
Our base-case forecast reaches $240.00 around 2029.
Implied market cap at $240.00: $14.64B
The multi-year forecast depicts a clear bullish trajectory, with notable milestones in key years. In 2030 the average price is $335.80, with a min of $254.67 and a max of $475.18, and a return on investment of 171.3% amid bullish sentiment. By 2040 the forecast shows an average of $1,041.76 (min $697.86, max $1,684.96) with a 741.7% ROI and bullish sentiment continuing.
In 2050 the forecast calls for an average of $2,416.69 (min $1,474.03, max $4,239.89) and a ROI of 1852.6%, with bullish sentiment persisting. Earlier years show a gradual rise from 2026, where the average is $123.77 (min $75.56, max $172.81) and ROI is 0% with neutral sentiment, through 2029, which shows a rising average near $276.54. The path from 2027 onward consistently shows bullish sentiment and rising averages, illustrating a long-run upside.
These are estimates, not guarantees, and reflect the stated forecast figures across the provided years. Investors should consider the implied risks and uncertainties inherent in long-horizon projections."
Tap a question to reveal the answer.
Average price is $335.80, with a min of $254.67 and a max of $475.18, and a return on investment of 171.3% with bullish sentiment.
The forecast shows bullish sentiment from 2027 onward with rising averages (e.g., 2027 $163.03, 2028 $207.55, 2029 $276.54, 2030 $335.80) and strong ROIs (e.g., 2030 171.3%, 2050 1852.6%), though 2026 is neutral with a 0% ROI.
Yes. In 2030 the max is $475.18, then in 2031 the max is $526.58, which would exceed $500.
Current price is $123.77 and market capitalization is $7.15B.
The 30-day range is $105.97 to $144.56. RSI14 is 70, SMA50 is $99.90, SMA200 is $86.91, with support at $91.83 and resistance at $117.28; sentiment is bullish.
Mirum Pharmaceuticals, Inc. Community Discussion
0Share your Mirum Pharmaceuticals, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.